(VIANEWS) – Novo Nordisk A/S (NVO), Neurocrine Biosciences (NBIX), Chipotle Mexican Grill (CMG) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Novo Nordisk A/S (NVO)
30% sales growth and 83.5% return on equity
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $4.05.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 39.48. Meaning, the purchaser of the share is investing $39.48 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 83.5%.
Volume
Today’s last reported volume for Novo Nordisk A/S is 863770 which is 35.17% below its average volume of 1332560.
Sales Growth
Novo Nordisk A/S’s sales growth is 49.4% for the ongoing quarter and 30% for the next.
Yearly Top and Bottom Value
Novo Nordisk A/S’s stock is valued at $159.88 at 01:22 EST, under its 52-week high of $172.97 and way above its 52-week low of $95.02.
2. Neurocrine Biosciences (NBIX)
23.9% sales growth and 4.16% return on equity
Neurocrine Biosciences, Inc., a neuroscience-focused biopharmaceutical company, discovers, develops, and delivers various treatments for people with neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products also include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; NBI-827104 to treat rare pediatric epilepsy and other indications; and crinecerfont. The company's products in clinical development also comprise NBI-1065844 for the treatment of negative symptoms of schizophrenia; NBI-1065845 for the treatment of resistant depression; and NBI-1065846 for treating anhedonia in depression. It has license and collaboration agreements with Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL – Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; AbbVie Inc.; and Sentia Medical Sciences Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Neurocrine Biosciences has a trailing twelve months EPS of $0.62.
PE Ratio
Neurocrine Biosciences has a trailing twelve months price to earnings ratio of 152.1. Meaning, the purchaser of the share is investing $152.1 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.16%.
Yearly Top and Bottom Value
Neurocrine Biosciences’s stock is valued at $94.30 at 01:22 EST, way below its 52-week high of $129.29 and above its 52-week low of $89.04.
Revenue Growth
Year-on-year quarterly revenue growth grew by 35.4%, now sitting on 1.6B for the twelve trailing months.
Volume
Today’s last reported volume for Neurocrine Biosciences is 1052040 which is 41.49% above its average volume of 743496.
3. Chipotle Mexican Grill (CMG)
12.4% sales growth and 44.74% return on equity
Chipotle Mexican Grill, Inc., together with its subsidiaries, owns and operates Chipotle Mexican Grill restaurants. It offers burritos, burrito bowls, quesadillas, tacos, and salads. The company was founded in 1993 and is headquartered in Newport Beach, California.
Earnings Per Share
As for profitability, Chipotle Mexican Grill has a trailing twelve months EPS of $37.37.
PE Ratio
Chipotle Mexican Grill has a trailing twelve months price to earnings ratio of 54.62. Meaning, the purchaser of the share is investing $54.62 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 44.74%.
Sales Growth
Chipotle Mexican Grill’s sales growth is 13.9% for the ongoing quarter and 12.4% for the next.
Moving Average
Chipotle Mexican Grill’s value is under its 50-day moving average of $2,064.69 and way higher than its 200-day moving average of $1,695.21.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.2%, now sitting on 8.98B for the twelve trailing months.
Volume
Today’s last reported volume for Chipotle Mexican Grill is 138706 which is 52.88% below its average volume of 294429.
4. The Cheesecake Factory Incorporated (CAKE)
7.2% sales growth and 14.66% return on equity
The Cheesecake Factory Incorporated operates restaurants. It operates two bakeries that produces cheesecakes and other baked products for its restaurants, international licensees, third-party bakery customers, external foodservice operators, retailers, and distributors. As of October 27, 2022, the company owned and operated 312 restaurants in the United States and Canada under brands, including The Cheesecake Factory, North Italia, and a collection of Fox Restaurant Concepts, as well as 29 The Cheesecake Factory restaurants under licensing agreements internationally. The Cheesecake Factory Incorporated was founded in 1972 and is headquartered in Calabasas, California.
Earnings Per Share
As for profitability, The Cheesecake Factory Incorporated has a trailing twelve months EPS of $0.97.
PE Ratio
The Cheesecake Factory Incorporated has a trailing twelve months price to earnings ratio of 36.94. Meaning, the purchaser of the share is investing $36.94 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.66%.
